Pharming Group N.V.

NasdaqGM:PHAR Stock Report

Market Cap: US$925.8m

Pharming Group Management

Management criteria checks 3/4

Pharming Group's CEO is Fabrice Chouraqui, appointed in Mar 2025, has a tenure of 1.33 years. total yearly compensation is $1.84M, comprised of 37.3% salary and 62.7% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth $8.70M. The average tenure of the management team and the board of directors is 2.8 years and 5.2 years respectively.

Key information

Fabrice Chouraqui

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage37.31%
CEO tenure1.3yrs
CEO ownership0.9%
Management average tenure2.8yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

Seeking Alpha • Feb 04

Pharming Group: Crossing From Speculation To Profitability

Summary Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs. The company's commercial infrastructure and pipeline expansion position it for significant upside as rare disease market opportunities broaden. Read the full article on Seeking Alpha
Seeking Alpha • Apr 01

Pharming Group: Small Dutch Company With Strong Revenues

Summary Pharming Group, a Dutch biotech firm, excels with RUCONEST and JOENJA, showing strong revenue growth and positive cash flow despite low US trading volume. RUCONEST and JOENJA drive revenue, with RUCONEST contributing $252.2M and JOENJA surging 147% to $45M in its first full year. Acquired KL1333, a promising late-stage molecule for mitochondrial diseases, enhancing their pipeline and expanding market potential. Despite low US trading volume, Pharming Group's robust financials and growth prospects make it a compelling investment for those with access to Euronext. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Pharming's rare immunodeficiency disorder drug gets FDA priority review

The U.S. Food and Drug Administration ((FDA) granted priority review to Pharming (NASDAQ:PHAR) application seeking approval of oral drug leniolisib to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in patients 12 years of age and older in the U.S. The FDA accepted the company's New Drug Application (NDA) and is expected to make a decision by March 29, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 2/3 study of leniolisib, which met its co-primary goals of reduction in index lymph node size and correction of immunodeficiency, the Netherlands-based company said in a Sept. 28 press release. APDS is a rare immunodeficiency disease that affects 1 to 2 people per million and is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells, according to the company.
Seeking Alpha • Aug 01

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

A committee of the European Medicines Agency (EMA) granted accelerated assessment for Pharming's (NASDAQ:PHAR) potential application seeking approval of leniolisib to treat patients aged 12 years and older with activated phosphoinositide 3-kinase (PI3K) delta syndrome (APDS). The company said it plans to submit the marketing authorization application (MAA) to the EMA in October. Pharming noted that an accelerated assessment reduces the timeframe for review by the EMA's Committee for Medicinal Products for Human Use (CHMP) to 150 days from 210 days. The company said clinical development for leniolisib includes positive data from a phase 2/3 trial. APDS is a rare immunodeficiency disease that affects 1 to 2 people per million and is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells, the company said in an Aug. 1 press release.

CEO Compensation Analysis

How has Fabrice Chouraqui's remuneration changed compared to Pharming Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$12m

Dec 31 2025US$2mUS$688k

US$3m

Compensation vs Market: Fabrice's total compensation ($USD1.84M) is below average for companies of similar size in the US market ($USD3.55M).

Compensation vs Earnings: Insufficient data to compare Fabrice's compensation with company performance.

CEO

Fabrice Chouraqui

1.3yrs
Tenure
US$1,844,000
Compensation

Mr. Fabrice Chouraqui, Ph D., PharmD, M.B.A., serves as the Chief Executive Officer and Executive Director of Pharming Group N.V. since March 4, 2025. He served as the Chief Executive Officer at Cellarity,...

Leadership Team

NamePositionTenureCompensationOwnership
Fabrice Chouraqui
CEO & Executive Director1.3yrsUS$1.84m0.94%
$ 8.7m
Kenneth Lynard
Chief Financial Officerless than a yearno datano data
Mireille Sanders
Chief Operations Officer6.9yrsno data0.17%
$ 1.6m
Michael Levitan
VP of Investor Relations & Corporate Communicationsno datano datano data
Ruud Van Outersterp
Chief Legal & Compliance Officer and Company Secretary5.2yrsno data0.11%
$ 1.0m
Ines Bernal
Chief People Officer1.6yrsno data0.018%
$ 165.5k
Anurag Relan
Chief Medical Officer5.1yrsno data0.14%
$ 1.3m
Alexander Breidenbach
Chief Business Officer2.8yrsno data0.059%
$ 547.3k
Leverne Marsh
Chief Commercial Officerless than a yearno datano data
Magnus Hansson
Medical Directorno datano datano data
Bruno M. Giannetti
Consultant5.1yrsno datano data
2.8yrs
Average Tenure
58yo
Average Age

Experienced Management: PHAR's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Fabrice Chouraqui
CEO & Executive Director1.3yrsUS$1.84m0.94%
$ 8.7m
Leonard Kruimer
Independent Non-Executive Director5.2yrsUS$109.00k0.027%
$ 250.6k
Mark Pykett
Independent Non-Executive Vice Chairman5.6yrsUS$100.00k0.031%
$ 283.2k
Barbara Yanni
Independent Non-Executive Director5.6yrsUS$114.00k0.031%
$ 283.2k
Richard Peters
Non-Executive Chairman of Board2.8yrsUS$167.00k0.022%
$ 204.7k
Elaine Sullivan
Non Executive Director1.1yrsUS$73.00k0.0085%
$ 78.3k
Jabine T. M. van Meijs
Independent Non-Executive Director5.2yrsUS$114.00k0.027%
$ 250.6k
5.2yrs
Average Tenure
64.5yo
Average Age

Experienced Board: PHAR's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/17 00:05
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharming Group N.V. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
John SavinEdison Investment Research
Simon ScholesFirst Berlin Equity Research GmbH